Ovid Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Ovid Therapeutics'in kazancının yıllık 20.6% oranında azalması, yıllık gelirinin ise yıllık 50.5% oranında artması beklenmektedir. EPS'nin düşmesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -168.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

-20.6%

Kazanç büyüme oranı

-12.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.4%
Gelir büyüme oranı	50.5%
Gelecekteki özkaynak getirisi	-168.1%
Analist kapsamı	Good
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:OVID - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	22	-29	N/A	N/A	4
12/31/2025	5	-43	N/A	N/A	6
12/31/2024	1	-34	N/A	N/A	7
9/30/2024	1	-33	-58	-58	N/A
6/30/2024	1	-30	-53	-53	N/A
3/31/2024	0	-51	-50	-50	N/A
12/31/2023	0	-52	-46	-46	N/A
9/30/2023	0	-49	-43	-43	N/A
6/30/2023	0	-49	-46	-46	N/A
3/31/2023	0	-51	-49	-47	N/A
12/31/2022	2	-54	-57	-55	N/A
9/30/2022	1	-68	-60	-58	N/A
6/30/2022	1	-66	-58	-56	N/A
3/31/2022	1	-67	-63	-62	N/A
12/31/2021	208	120	118	119	N/A
9/30/2021	214	123	116	116	N/A
6/30/2021	221	117	125	126	N/A
3/31/2021	221	110	128	128	N/A
12/31/2020	13	-81	-52	-52	N/A
9/30/2020	7	-76	-54	-54	N/A
6/30/2020	N/A	-76	-62	-62	N/A
3/31/2020	N/A	-67	-57	-57	N/A
12/31/2019	N/A	-60	-51	-51	N/A
9/30/2019	N/A	-56	-45	-45	N/A
6/30/2019	N/A	-53	-46	-46	N/A
3/31/2019	N/A	-53	-46	-45	N/A
12/31/2018	N/A	-52	-46	-46	N/A
9/30/2018	N/A	-50	-44	-44	N/A
6/30/2018	N/A	-46	N/A	-43	N/A
3/31/2018	N/A	-44	N/A	-37	N/A
12/31/2017	N/A	-65	N/A	-31	N/A
9/30/2017	N/A	-61	N/A	-28	N/A
6/30/2017	N/A	-58	N/A	-23	N/A
3/31/2017	N/A	-53	N/A	-21	N/A
12/31/2016	N/A	-22	N/A	-18	N/A
9/30/2016	N/A	-18	N/A	-14	N/A
12/31/2015	N/A	-13	N/A	-5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OVID önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: OVID önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: OVID önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: OVID şirketinin gelirinin (yıllık 50.5% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OVID şirketinin gelirinin (yıllık 50.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OVID 3 yıl içinde kârsız olması bekleniyor.

Ovid Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 45%, EPS downgraded

Consensus revenue estimates decrease by 87%, EPS upgraded

Consensus revenue estimates fall by 80%

Consensus revenue estimates increase by 1,902%

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Recent updates

Consensus revenue estimates increase by 45%, EPS downgraded

New major risk - Financial position

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ovid Therapeutics Appoints Dr. Amanda Banks, as Chief Development Officer

Ovid Therapeutics Inc. Expands Scientific Advisory Board

Ovid Therapeutics Inc. Announces That eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Small Cap Comp Value Index

Ovid Therapeutics Inc. and Graviton Bioscience Corporation Announce Topline Data from A Phase 1 Clinical Trial Studying OV888/GV101 Capsule

Consensus revenue estimates decrease by 87%, EPS upgraded

Consensus revenue estimates fall by 80%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ovid Therapeutics Inc., Annual General Meeting, Jun 06, 2024

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

President recently bought US$50k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus revenue estimates increase by 1,902%

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Consensus revenue estimates increase by 48%

Ovid Therapeutics Inc. Announces Changes to Its Board

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Consensus revenue estimates increase by 14%

Price target increased by 7.1% to US$5.00

Consensus revenue estimates increase by 60%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Ovid Therapeutics Doses Healthy Volunteers with OV329 in Phase 1 Trial

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2021)

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in 2Q 2021)

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Price target decreased to US$4.70

Ovid Therapeutics Inc., Annual General Meeting, Jun 09, 2022

Price target increased to US$5.50

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to US$5.50

President & Chief Medical Officer notifies of intention to sell stock

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 3000E Index

Treasurer & Corporate Controller Timothy Daly has left the company

Ovid Therapeutics: Good Entry Point For Investors

Ovid Therapeutics appoints Jeff Rona as CFO

Price target decreased to US$4.88

Investor sentiment improved over the past week

Price target decreased to US$5.40

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

New 90-day high: US$4.04

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

New 90-day low: US$2.42

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Analysts increase revenue estimates to US$11.1m

Ovid Therapeutics Inc. Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

Ovid Therapeutics misses goal in Angelman syndrome treatment

New 90-day high: US$6.84

Price target raised to US$14.67

Revenue beats expectations, earnings disappoint